Full metadata record
DC FieldValueLanguage
dc.contributor.authorLarsson, Mikaelen_US
dc.contributor.authorHuang, Wei-Tingen_US
dc.contributor.authorLiu, Dean-Moen_US
dc.contributor.authorLosic, Dusanen_US
dc.date.accessioned2018-08-21T05:54:02Z-
dc.date.available2018-08-21T05:54:02Z-
dc.date.issued2017-04-01en_US
dc.identifier.issn0305-7372en_US
dc.identifier.urihttp://dx.doi.org/10.1016/j.ctrv.2017.03.004en_US
dc.identifier.urihttp://hdl.handle.net/11536/145510-
dc.description.abstractGene-silencing miRNA and siRNA are emerging as attractive therapeutics with potential to suppress any genes, which could be especially useful in combination cancer therapy to overcome multidrug resistant (MDR) cancer. Nanomedicine aims to advance cancer treatment through functional nanocarriers that delivers one or more therapeutics to cancer tissue and cells with minimal off-target effects and suitable release kinetics and dosages. Although much effort has gone into developing circulating nanocarriers with targeting functionality for systemic administration, another alternative and straightforward approach is to utilize formulations to be administered directly to the site of action, such as pulmonary and intratumoral delivery. The combination of gene-silencing RNA with drugs in nanocarriers for localized delivery is emerging with promising results. In this review, the current progress and strategies for local co-administration of RNA and drug for synergistic effects and future potential in cancer treatment are presented and discussed. Key advances in RNA-drug anticancer synergy and localized delivery systems were combined with a review of the available literature on local co-administration of RNA and drug for cancer treatment. It is concluded that advanced delivery systems for local administration of gene-silencing RNA and drug hold potential in treatment of cancer, depending on indication. In particular, there are promising developments using pulmonary delivery and intratumoral delivery in murine models, but further research should be conducted on other local administration strategies, designs that achieve effective intracellular delivery and maximize synergy and feasibility for clinical use. (C) 2017 Elsevier Ltd. All rights reserved.en_US
dc.language.isoen_USen_US
dc.subjectDrug delivery systemen_US
dc.subjectCombinatory treatmenten_US
dc.subjectTumoren_US
dc.subjectSynergyen_US
dc.subjectRNAen_US
dc.subjectTherapeutic substanceen_US
dc.titleLocal co-administration of gene-silencing RNA and drugs in cancer therapy: State-of-the art and therapeutic potentialen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ctrv.2017.03.004en_US
dc.identifier.journalCANCER TREATMENT REVIEWSen_US
dc.citation.volume55en_US
dc.citation.spage128en_US
dc.citation.epage135en_US
dc.contributor.department材料科學與工程學系zh_TW
dc.contributor.departmentDepartment of Materials Science and Engineeringen_US
dc.identifier.wosnumberWOS:000401377800013en_US
Appears in Collections:Articles